Clinical-stage drug discovery, development, and manufacturing company specializing in cancer therapeutics.
Sutro Biopharma, Inc., headquartered in South San Francisco, California, is an innovative clinical-stage company specializing in drug discovery, development, and manufacturing. Employing its advanced XpressCF+ platform, which integrates cell-free protein synthesis and site-specific conjugation technologies, Sutro Biopharma focuses on creating novel protein therapeutics for cancer and autoimmune disorders.
The company's robust pipeline includes promising candidates such as STRO-001 and STRO-002, both in Phase 1 clinical trials. STRO-001 is an antibody-drug conjgugate (ADC) targeting CD74, designed for patients battling multiple myeloma and non-Hodgkin lymphoma. Meanwhile, STRO-002 targets folate receptor-alpha, addressing ovarian and endometrial cancers. These initiatives underscore Sutro Biopharma's commitment to advancing precision therapies that address critical unmet needs in oncology.
Sutro Biopharma has cultivated strategic collaborations and licensing agreements to further enhance its research capabilities. Partnerships with Merck and Celgene Corporation focus on developing cytokine derivatives for cancer and autoimmune disorders, as well as bispecific antibodies and ADCs in the field of immuno-oncology. These collaborations bolster the company's ability to explore cutting-edge therapeutic approaches and expand its impact in the global healthcare landscape.
Originally incorporated as Fundamental Applied Biology, Inc., in 2003, the company rebranded to Sutro Biopharma, Inc., reflecting its evolution and dedication to pioneering biopharmaceutical innovation. With a steadfast commitment to scientific excellence and transformative therapies, Sutro Biopharma continues to push the boundaries of medical research to improve outcomes for patients worldwide.